Your browser doesn't support javascript.
loading
From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang, Zijian; Zhou, Chunyang; Zhang, Yiming; Tian, Xinchen; Wang, Haochen; Wu, Jibiao; Jiang, Shulong.
Afiliação
  • Wang Z; College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Zhou C; Department of Radiation Oncology, Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University, Qingdao, China.
  • Zhang Y; Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
  • Tian X; Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
  • Wang H; Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China.
  • Wu J; College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: wujibiao1963@163.com.
  • Jiang S; Clinical Medical Laboratory Center, Jining First People's Hospital, Shandong First Medical University, Jining, Shandong, China; College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China. Electronic address: jnsljiang@163.com.
Biomed Pharmacother ; 170: 116074, 2024 Jan.
Article em En | MEDLINE | ID: mdl-38147732
ABSTRACT
Hepatocellular carcinoma (HCC) remains a major global health burden, and sorafenib, a multi-kinase inhibitor, has shown effectiveness in the treatment of HCC and is considered as the first-line therapy for advanced HCC. However, the response to sorafenib varies among patients, and the development of drug resistance poses a prevalent obstacle. Ferroptosis, a newly characterized form of cell death featured by iron-dependent lipid peroxidation, has emerged as a critical player in the reaction to sorafenib therapy in HCC. The induction of ferroptosis has been shown to augment the anticancer benefits of sorafenib. However, it has also been observed to contribute to sorafenib resistance. This review presents a comprehensive and thorough analysis that elucidates the intricate relationship between ferroptosis and sorafenib over recent years, aiming to formulate effective therapeutic approaches for liver cancer. Based on this exploration, we propose innovative strategies intended to overcome sorafenib resistance via targeted modulation of ferroptosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ferroptose / Neoplasias Hepáticas / Antineoplásicos Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Ferroptose / Neoplasias Hepáticas / Antineoplásicos Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China